Ocular Therapeutix OCUL Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $10.79M-18.6% | $13.25M-8.9% | $14.54M+8.1% | $13.46M+25.8% | $10.7M-37.4% | ||
| $1.33M-16.6% | $1.59M-10.1% | $1.77M-8.7% | $1.94M+54.0% | $1.26M+2.6% | ||
| $9.46M-18.9% | $11.66M-8.7% | $12.77M+10.9% | $11.52M+22.0% | $9.44M-40.5% | ||
| 87.7%-0.3pp | 88%+0.2pp | 87.8%+2.2pp | 85.6%-2.6pp | 88.2%-4.6pp | ||
| $66.21M+30.3% | $50.8M-3.0% | $52.36M+2.5% | $51.08M+19.2% | $42.86M+4.6% | ||
| $16.58M+27.9% | $12.96M-1.0% | $13.09M-4.7% | $13.73M-3.0% | $14.15M+30.5% | ||
| $20.01M+13.3% | $17.66M+10.2% | $16.02M+11.7% | $14.35M-12.2% | $16.35M+12.0% | ||
| $104.13M+25.4% | $83.01M-0.3% | $83.24M+2.6% | $81.1M+8.7% | $74.62M+10.3% | ||
| -$93.34M-33.8% | -$69.76M-1.5% | -$68.7M-1.6% | -$67.64M-5.8% | -$63.92M-26.4% | ||
| -865.5%-339pp | -526.5%-54.1pp | -472.3%+30.2pp | -502.6%+94.9pp | -597.5%-301pp | ||
| $2.78M-1.9% | $2.83M-5.7% | $3M-0.5% | $3.02M+1.1% | $2.98M-3.9% | ||
| $4.73M-7.4% | $5.11M+809% | -$720K-316% | -$173K-27.2% | -$136K— | ||
| -$88.61M-37.1% | -$64.65M+6.9% | -$69.42M-2.4% | -$67.81M-5.9% | -$64.05M-32.4% | ||
| -821.6%-334pp | -488%-10.7pp | -477.3%+26.6pp | -503.9%+94.9pp | -598.7%-315pp | ||
| -$0.40-48.1% | -$0.27+28.9% | -$0.38+2.6% | -$0.39-2.6% | -$0.38-35.7% | ||
| -$92.06M-34.4% | -$68.51M-1.3% | -$67.63M-1.5% | -$66.62M-5.8% | -$62.94M-26.8% | ||
| -853.6%-336pp | -517.1%-52.1pp | -465%+30.0pp | -494.9%+93.3pp | -588.3%-298pp | ||
| -$93.34M-33.8% | -$69.76M-1.5% | -$68.7M-1.6% | -$67.64M-5.8% | -$63.92M-26.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Ocular Therapeutix's revenue?
- Ocular Therapeutix (OCUL) generated $52.0M in revenue over the trailing twelve months, down 12.8% year over year.
- Is Ocular Therapeutix profitable?
- Ocular Therapeutix is not currently profitable: it reported a net loss of $290.5M over the trailing twelve months, a -558.2% net margin.
- What are Ocular Therapeutix's profit margins?
- Gross margin is 87.2% and operating margin is -575.4%, with a -558.2% net margin.
- What is Ocular Therapeutix's earnings per share?
- Ocular Therapeutix's diluted EPS over the trailing twelve months is $-1.44.
- Where does Ocular Therapeutix's income statement data come from?
- Every line is extracted from Ocular Therapeutix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
